🏛️ Verified NIH Record • Updated 2026-02-04
Assessing DCog Short for Neurotoxicity in CAR-T (NCT07403812)
🟡 Not Yet Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Beth Israel Deaconess Medical Center
🩺 Plain-English Summary (8th-Grade Level)
The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (6 items).
Location: Beth Israel Deaconess Medical Center — Boston, Massachusetts
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- patients \< 18 years old
- pregnant women
- prisoners
- adults unable to consent,
- participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.